{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:39:29Z","timestamp":1791607169799,"version":"4.3.4"},"reference-count":146,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Oradea"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Obesity is a chronic disease with high prevalence and associated comorbidities, making it a growing global concern. These comorbidities include type 2 diabetes, hypertension, ventilatory dysfunction, arthrosis, venous and lymphatic circulation diseases, depression, and others, which have a negative impact on health and increase morbidity and mortality. GLP-1 agonists, used to treat type 2 diabetes, have been shown to be effective in promoting weight loss in preclinical and clinical studies. This review summarizes numerous studies conducted on the main drugs in the GLP-1 agonists class, outlining the maximum achievable weight loss. Our aim is to emphasize the active role and main outcomes of GLP-1 agonists in promoting weight loss, as well as in improving hyperglycemia, insulin sensitivity, blood pressure, cardio\u2013metabolic, and renal protection. We highlight the pleiotropic effects of these medications, along with their indications, contraindications, and precautions for both diabetic and non-diabetic patients, based on long-term follow-up studies.<\/jats:p>","DOI":"10.3390\/ijms241310449","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T01:49:32Z","timestamp":1687398572000},"page":"10449","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":272,"title":["Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials"],"prefix":"10.3390","volume":"24","author":[{"given":"Mihaela-Simona","family":"Popoviciu","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Pharmacy, University of Oradea, P-ta 1 Decembrie 10, 410073 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"P\u0103duraru","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, University of Oradea, P-ta 1 Decembrie 10, 410073 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galal","family":"Yahya","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Al Sharqia 44519, Egypt"},{"name":"Department of Molecular Genetics, Faculty of Biology, Technical University of Kaiserslautern, Paul-Ehrlich Str. 24, 67663 Kaiserslautern, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Metwally","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia"},{"name":"Department of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7810-8925","authenticated-orcid":false,"given":"Simona","family":"Cavalu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, University of Oradea, P-ta 1 Decembrie 10, 410073 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"ref_1","unstructured":"Ritchie, H., and Roser, M. (2023, January 10). \u201cObesity\u201d. Published online at OurWorldInData.org. Available online: https:\/\/ourworldindata.org\/obesity."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.2337\/diacare.28.9.2322","article-title":"Point: Visceral Adiposity Is Causally Related to Insulin Resistance","volume":"28","author":"Lebovitz","year":"2005","journal-title":"Diabetes Care"},{"key":"ref_3","first-page":"s176","article-title":"Obesity: Definition, comorbidities, causes, and burden","volume":"22","author":"Apovian","year":"2016","journal-title":"Am. J. Manag. Care"},{"key":"ref_4","unstructured":"(2022). WHO European Regional Obesity Report 2022, WHO Regional Office for Europe."},{"key":"ref_5","first-page":"64","article-title":"Obesity and Health-Related lifestyle factors in the general population in romania: A cross sectional study","volume":"11","author":"Roman","year":"2015","journal-title":"Acta Endocrinol."},{"key":"ref_6","unstructured":"NCD-RisC (2023, February 15). Homepage > NCD-RisC. Available online: https:\/\/www.ncdrisc.org\/."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"642","DOI":"10.4158\/EP12160.PS","article-title":"American Association of Clinical Endocrinologists\u2019 Position Statement on Obesity and Obesity Medicine","volume":"18","author":"Mechanick","year":"2012","journal-title":"Endocr. Pract."},{"key":"ref_8","first-page":"397","article-title":"Body mass index and patterns of mortality amongst Seventh-day Adventist men","volume":"15","author":"Lindsted","year":"1991","journal-title":"Int. J. Obes."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"864","DOI":"10.4158\/EP13263.RA","article-title":"New Tools for Weight-Loss Therapy Enable a More Robust Medical Model for Obesity Treatment: Rationale for a Complications-Centric Approach","volume":"19","author":"Garvey","year":"2013","journal-title":"Endocr. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American association of clinical endocrinologists and american college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jacc.2019.11.044","article-title":"Cardiometabolic-based chronic disease, adiposity and dysglycemia drivers: JACC state-of-the-art review","volume":"75","author":"Mechanick","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e1339","DOI":"10.1210\/clinem\/dgab848","article-title":"New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications","volume":"107","author":"Garvey","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/j.1550-8528.1999.tb00436.x","article-title":"Reduction in incidence of diabetes, hypertension and lipid disturbances after interventional weight loss induced by bariatric surgery: The SOS Intervention Study","volume":"7","author":"Sjostrom","year":"1999","journal-title":"Obes. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1001\/archinte.162.16.1867","article-title":"Overweight and obesity as determinants of cardiovascular risk: The Framingham experience","volume":"162","author":"Wilson","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1001\/jama.1994.03510350050036","article-title":"Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study","volume":"271","author":"Benjamin","year":"1994","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7326\/0003-4819-122-7-199504010-00001","article-title":"Weight Gain as a Risk Factor for Clinical Diabetes Mellitus in Women","volume":"122","author":"Colditz","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1056\/NEJMoa050080","article-title":"Normal Fasting Plasma Glucose Levels and Type 2 Diabetes in Young Men","volume":"353","author":"Tirosh","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_18","first-page":"641","article-title":"Metabolic and health complications of obesity","volume":"36","author":"Grundy","year":"1990","journal-title":"Dis. Mon."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.hco.0000200416.65370.a0","article-title":"Diagnosis and management of the metabolic syndrome. An American Heart Association\/National Heart, Lung, and Blood Institute scientific statement","volume":"21","author":"Grundy","year":"2006","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s13665-015-0108-6","article-title":"Obesity hypoventilation syndrome","volume":"4","author":"Shetty","year":"2015","journal-title":"Curr. Pulmonol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1001\/archinte.159.21.2582","article-title":"Prospective study of body mass index, weight change and risk of adult-onset asthma in women","volume":"159","author":"Canargo","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1053\/j.gastro.2016.12.052","article-title":"Gastrointestinal Complications of Obesity","volume":"152","author":"Camilleri","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0002-9343(99)00121-7","article-title":"Risk factors associated with symptoms of gastroesophageal reflux","volume":"106","author":"Locke","year":"1999","journal-title":"Am. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12011-015-0361-0","article-title":"New Evidences of Key Factors Involved in \u201cSilent Stones\u201d Etiopathogenesis and Trace Elements: Microscopic, Spectroscopic, and Biochemical Approach","volume":"168","author":"Cavalu","year":"2015","journal-title":"Biol.Trace Elem. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1067\/mva.2003.61","article-title":"Does severe venous insufficiency have a different etiology in the morbidly obese? Is it venous?","volume":"37","author":"Padberg","year":"2003","journal-title":"J. Vasc. Surg."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Barlow, S.E., and Dietz, W.H. (1998). Obesity Evaluation and Treatment: Expert Committee Recommendations. Pediatrics, 102.","DOI":"10.1542\/peds.102.3.e29"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1053\/meta.2001.24210","article-title":"Relationship between insulin resistance, weight loss, and coronary heart disease in healthy, obese women","volume":"50","author":"McLaughlin","year":"2001","journal-title":"Metabolism"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6365","DOI":"10.1038\/sj.onc.1207751","article-title":"Obesity and cancer","volume":"23","author":"Calle","year":"2004","journal-title":"Oncogene"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/S0140-6736(05)67725-2","article-title":"Causes of cancer in the world: Comparative risk assessment of nine behavioural and environmental risk factors","volume":"366","author":"Danaei","year":"2005","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ijc.11186","article-title":"Effect of family history, obesity and exercise on breast cancer risk among postmenopausal women","volume":"106","author":"Carpenter","year":"2003","journal-title":"Int. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Vainio, H., and Bianchini, F. (2002). Weight Control and Physical Activity, IARC.","DOI":"10.1046\/j.1467-789X.2002.00046.x"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"The Rotterdam ESHRE\/ASRM-sponsored PCOS Consensus Workshop Group (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril., 81, 19\u201325.","DOI":"10.1016\/j.fertnstert.2003.10.004"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Asfari, M.M., Sarmini, M.T., Baidoun, F., Al-Khadra, Y., Ezzaizi, Y., Dasarathy, S., and McCullough, A. (2020). Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome. BMJ Open Gastroenterol., 7.","DOI":"10.1136\/bmjgast-2019-000352"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Alorabi, M., Cavalu, S., Al-kuraishy, H.M., Al-Gareeb, A.I., Mostafa-Hedeab, G., Negm, W.A., Youssef, A., El-Kadem, A.H., Saad, H.M., and El-Saber Batiha, G. (2022). Pentoxifylline and berberine mitigate diclofenac-induced acute nephrotoxicity in male rats via modulation of inflammation and oxidative stress. Biomed. Pharmacother., 152.","DOI":"10.1016\/j.biopha.2022.113225"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Baig, M.S., Banu, A., Zehravi, M., Rana, R., Burle, S.S., Khan, S.L., Islam, F., Siddiqui, F.A., Massoud, E.E.S., and Rahman, M.H. (2022). An Overview of Diabetic Foot Ulcers and Associated Problems with Special Emphasis on Treatments with Antimicrobials. Life, 12.","DOI":"10.3390\/life12071054"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14290","article-title":"Obesity as a multisystem disease: Trends in obesity rates and obesity-related complications","volume":"23","author":"Sarma","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s13679-015-0164-9","article-title":"An Overview of Links Between Obesity and Mental Health","volume":"4","author":"Avila","year":"2015","journal-title":"Curr. Obes. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.medj.2020.06.005","article-title":"When two pandemics meet: Why is obesity associated with increased COVID-19 mortality?","volume":"1","author":"Lockhart","year":"2020","journal-title":"Med"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1042\/CS20120223","article-title":"The defence of body weight: A physiological basis for weight regain after weight loss","volume":"124","author":"Sumithran","year":"2013","journal-title":"Clin. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM199503093321001","article-title":"Changes in Energy Expenditure Resulting from Altered Body Weight","volume":"332","author":"Leibel","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_41","first-page":"205","article-title":"Safety and mechanism of action of orlistat (tetrahydrolipstatin) as the first local antiobesity drug","volume":"2","year":"2006","journal-title":"J. Appl. Sci. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ijo.2015.220","article-title":"Altered gut and adipose tissue hormones in overweight and obese individuals: Cause or consequence?","volume":"40","author":"Lean","year":"2016","journal-title":"Int. J. Obes."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Anderson, S.L., Beutel, T.R., and Trujillo, J.M. (2020). Oral semaglutide in type 2 diabetes. J. Diabetes Its Complicat., 34.","DOI":"10.1016\/j.jdiacomp.2019.107520"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1476-5381.2011.01687.x","article-title":"The structure and function of the glucagon-like peptide-1 receptor and its ligands","volume":"166","author":"Donnelly","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1464-5491.2009.02790.x","article-title":"Exenatide efficacy and safety: A systematic review","volume":"26","author":"Norris","year":"2009","journal-title":"Diabet. Med."},{"key":"ref_47","first-page":"503","article-title":"Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus","volume":"12","author":"Christensen","year":"2009","journal-title":"IDrugs Investig. Drugs J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/cmdc.201700781","article-title":"Glucagon-like peptide-1 (GLP-1)-based therapeutics: Current status and future opportunities beyond type 2 diabetes","volume":"13","author":"Cheang","year":"2018","journal-title":"ChemMedChem"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2147\/DDDT.S358989","article-title":"Designing a Dual GLP-1R\/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP","volume":"16","author":"Wang","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1080\/14712598.2016.1240780","article-title":"Albiglutide: A unique GLP-1 receptor agonist","volume":"16","author":"Rendell","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.drudis.2013.05.011","article-title":"Future directions for peptide therapeutics development","volume":"18","author":"Kaspar","year":"2013","journal-title":"Drug Discov. Today"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.neuroimage.2006.12.035","article-title":"Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans","volume":"35","author":"Pannacciulli","year":"2007","journal-title":"NeuroImage"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/302703a0","article-title":"Rapid development of tolerance to the behavioural actions of cholecystokinin","volume":"302","author":"Crawley","year":"1983","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2337\/dc10-0518","article-title":"Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues: In vitro and ex vivo studies in humans","volume":"34","author":"Moon","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: Their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_59","first-page":"T1","article-title":"Effects of glucagon-like peptide 1 on appetite and body weight: Focus on the CNS","volume":"221","author":"Kulve","year":"2014","journal-title":"J. Endocrinol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.molcel.2020.09.020","article-title":"Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists","volume":"80","author":"Zhang","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/dc06-2375","article-title":"Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects with Type 2 Diabetes","volume":"30","author":"Kim","year":"2007","journal-title":"Diabetes Care"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/14656566.2018.1552258","article-title":"Oral semaglutide for the treatment of type 2 diabetes","volume":"20","author":"Hedrington","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Nauck, M.A., Quast, D.R., Wefers, J., and Meier, J.J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014State-of-the-art. Mol. Metab., 46.","DOI":"10.1016\/j.molmet.2020.101102"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/postgradmedj-2019-137186","article-title":"An overview of GLP-1 agonists and recent cardiovascular outcomes trials","volume":"96","author":"Sheahan","year":"2020","journal-title":"Postgrad. Med. J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre","year":"2009","journal-title":"Diabet. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination with Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)","volume":"32","author":"Zinman","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"ref_72","first-page":"72","article-title":"Liraglutide for Weight Management, Critical Analysis of Efficacy and Side effects in Non diabetic, individuals with obesity: A Comprehensive Systematic Review","volume":"19","author":"Kanwal","year":"2021","journal-title":"Middle East J. Fam. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00003495-200868020-00002","article-title":"Gut Hormones as Potential New Targets for Appetite Regulation and the Treatment of Obesity","volume":"68","author":"Field","year":"2008","journal-title":"Drugs"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and \u03b2-cell function in type 2 diabetes: A parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"key":"ref_75","first-page":"S187","article-title":"Incretin-based therapies in the management of type 2 diabetes: Rationale and reality in a managed care setting","volume":"16","author":"Garber","year":"2010","journal-title":"Am. J. Manag. Care"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2174\/138955709788452739","article-title":"Drug treatment of obesity: Established and emerging therapies","volume":"9","author":"Isidro","year":"2009","journal-title":"Mini-Rev. Med. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1463-1326.2010.01330.x","article-title":"Liraglutide\u2014Overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes","volume":"13","author":"Davies","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/ijo.2013.149","article-title":"Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults","volume":"38","author":"Lean","year":"2014","journal-title":"Int. J. Obes."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1475-2840-8-12","article-title":"Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone","volume":"8","author":"Sullivan","year":"2009","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: A randomised, double-blind trial","volume":"389","author":"Astrup","year":"2017","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial","volume":"52","author":"Vaag","year":"2009","journal-title":"Diabetologia"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/osp4.84","article-title":"Liraglutide for weight management: A critical review of the evidence","volume":"3","author":"Mehta","year":"2017","journal-title":"Obes. Sci. Pract."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40262-015-0343-6","article-title":"Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics","volume":"55","author":"Jacobsen","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(15)00436-2","article-title":"Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): A randomised, double-blind, placebo-controlled trial","volume":"4","author":"Dejgaard","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.4314\/ahs.v19i3.35","article-title":"The efficacy and safety of liraglutide in the obese, non-diabetic individuals: A systematic review and meta-analysis","volume":"19","author":"Zhang","year":"2019","journal-title":"Afr. Health Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/17512433.2021.1933433","article-title":"Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome","volume":"14","author":"Siamashvili","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/1573402114666180507152620","article-title":"Cardiovascular Effects of Liraglutide","volume":"15","author":"Mikhail","year":"2019","journal-title":"Curr. Hypertens. Rev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1517\/14740338.2015.987122","article-title":"Potential side effects to GLP-1 agonists: Understanding their safety and tolerability","volume":"14","author":"Consoli","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.2337\/db13-1909","article-title":"Incretin Therapy and Pancreatic Pathologies: Background Pathology Versus Drug-Induced Pathology in Rats","volume":"63","author":"Egan","year":"2014","journal-title":"Diabetes"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.diabres.2014.01.010","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials","volume":"103","author":"Monami","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2337\/dc16-2684","article-title":"Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight\/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program","volume":"40","author":"Steinberg","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","volume":"373","author":"Astrup","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1111\/dom.13420","article-title":"Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity","volume":"20","author":"Hausner","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/dom.12963","article-title":"Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials","volume":"19","author":"Aroda","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/dc14-2883","article-title":"Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial","volume":"39","author":"Davies","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4158\/EP10215.OR","article-title":"Mild renal impairment and the efficacy and safety of liraglutide","volume":"17","author":"Davidson","year":"2011","journal-title":"Endocr. Pract."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1080\/17425255.2016.1234608","article-title":"Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes","volume":"12","author":"Tomlinson","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/14656566.2019.1695779","article-title":"An evaluation of liraglutide including its efficacy and safety for the treatment of obesity","volume":"21","author":"Lin","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): A randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults with Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-Weekly Semaglutide in Adolescents with Obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Gao, X., Hua, X., Wang, X., Xu, W., Zhang, Y., Shi, C., and Gu, M. (2022). Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.935823"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2337\/cd19-0079","article-title":"Oral Semaglutide","volume":"38","author":"Hughes","year":"2020","journal-title":"Clin. Diabetes"},{"key":"ref_112","unstructured":"(2019). Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the Treatment of Adult Patients with Type 2 Diabetes Mellitus to Improve Glycemic Control, in Combination with Metformin (Second-Line Treatment), and in Combination with Metformin and Sulfonylurea (Third-Line Treatment) [Internet], Canadian Agency for Drugs and Technologies in Health."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/dom.12926","article-title":"Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): D ata from randomized controlled trials","volume":"19","author":"Monami","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"278","DOI":"10.7326\/M20-0864","article-title":"Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis","volume":"173","author":"Tsapas","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., and Sasso, F.C. (2023). GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021703"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Wong, C., Lee, M.H., Yaow, C.Y.L., Chin, Y.H., Goh, X.L., Ng, C.H., Lim, A.Y.L., Muthiah, M.D., and Khoo, C.M. (2021). Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.609110"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Davies","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): A randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Kahn","year":"2021","journal-title":"Lancet"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., and Rodr\u00edguez, \u00c1. (2022). Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA, 327.","DOI":"10.1001\/jama.2022.0078"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","article-title":"Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): A double-blind, multicentre, randomised, phase 3 trial","volume":"10","author":"Inagaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S2213-8587(22)00187-5","article-title":"Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): A multicentre, randomised, open-label, parallel-group, phase 3 trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_125","unstructured":"Farzam, K., and Patel, P. (2022). StatPearls [Internet], StatPearls Publishing."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2337\/dc11-1935","article-title":"Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)","volume":"35","author":"Fonseca","year":"2012","journal-title":"Diabetes Care"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.2337\/dc12-2006","article-title":"Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)","volume":"36","author":"Dimas","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2337\/dc12-2709","article-title":"Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)","volume":"36","author":"Rosenstock","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/dme.12328","article-title":"Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)","volume":"31","author":"Bolli","year":"2014","journal-title":"Diabet. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jdiacomp.2014.01.012","article-title":"Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)","volume":"28","author":"Rosenstock","year":"2014","journal-title":"J. Diabetes Its Complicat."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/dom.12121","article-title":"Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)","volume":"15","author":"Pinget","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.2337\/dc12-2454","article-title":"Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.2337\/dc12-2462","article-title":"Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.2337\/dc16-0014","article-title":"Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2337\/dc16-2143","article-title":"Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial","volume":"40","author":"Meneilly","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jdiacomp.2018.11.012","article-title":"Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study","volume":"33","author":"Wysham","year":"2019","journal-title":"J. Diabetes Its Complicat."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1464-5491.2011.03301.x","article-title":"DURATION-2: Efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide","volume":"28","author":"Wysham","year":"2011","journal-title":"Diabet. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/jc.2010-2081","article-title":"DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes","volume":"96","author":"Blevins","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","article-title":"Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study","volume":"381","author":"Buse","year":"2013","journal-title":"Lancet"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/dom.13266","article-title":"Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study","volume":"20","author":"Guja","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Wysham, C.H., Rosenstock, J., Vetter, M.L., Wang, H., Hardy, E., and Iqbal, N. (2020). Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study. BMJ Open Diabetes Res. Care, 8.","DOI":"10.1136\/bmjdrc-2019-000773"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/dom.12908","article-title":"Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study","volume":"19","author":"Gadde","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.2147\/DMSO.S319895","article-title":"A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives","volume":"14","author":"Reed","year":"2021","journal-title":"Diabetes Metab. Syndr. Obes. Targets Ther."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Tilinca, M.C., Tiuca, R.A., Niculas, C., Varga, A., and Tilea, I. (2021). Future perspectives in diabesity treatment: Semaglutide, a glucagon-like peptide 1 receptor agonist (Review). Exp. Ther. Med., 22.","DOI":"10.3892\/etm.2021.10601"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2337\/dc11-1233","article-title":"Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks","volume":"35","author":"Diamant","year":"2012","journal-title":"Diabetes Care"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2337\/dc11-1107","article-title":"Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study","volume":"35","author":"Cuddihy","year":"2012","journal-title":"Diabetes Care"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/10449\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:58:00Z","timestamp":1760126280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/10449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":146,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ijms241310449"],"URL":"https:\/\/doi.org\/10.3390\/ijms241310449","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]}}}